← Leaderboards

David W Haas

Vanderbilt University Medical Center

Google Scholar ↗PubMed ↗ORCID ↗

$38,631,058

Attributed

$60,580,757

Total exposure

24

Grants

17

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$60,580,757 · 24

By mechanism

UM1$30,407,592 · 1

R01$13,995,886 · 2

U01$8,543,453 · 1

P30$5,858,489 · 4

U54$1,539,645 · 1

M01$235,692 · 15

Top collaborators

Most similar at Vanderbilt University Medical Center

Same institution · by research overlap

Spyros A Kalams$30,057,725
Rachel Margaret Presti$9,971,897
John C Gore$64,324,679
Xiaoyu Jiang$844,632
Devika Nair$351,432

Others in their field

Top investigators on “Research Personnel”

David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
Sonia M Thomas · Research Triangle Institute$700,865,642
Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
Tracy L Nolen · Research Triangle Institute$474,487,152
David R. Weir · University Of Michigan At Ann Arbor$364,053,504
Judith S. Currier · University Of California Los Angeles$284,675,012

Research focus

Research PersonnelClinical ResearchAcquired Immunodeficiency SyndromeCollaborationsResponseInfectionEpidemiologyAids Clinical Trial GroupProgramsHiv InfectionsFundingSpecimenDatabasesHiv-1CommunitiesClinical TrialsHuman SubjectCohortAids/Hiv ProblemMissionPersonsResourcesInstitutionAntiretroviral Therapy

Grant awards (92)

Vanderbilt HIV Clinical Trials Unit (CTU)$2,720,209

UM1 · FY2025 · AI · contact PI

Pharmacogenomics of HIV Therapy$806,550

R01 · FY2025 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit (CTU)$2,649,501

UM1 · FY2024 · AI · contact PI

Pharmacogenomics of HIV Therapy$814,885

R01 · FY2024 · AI · contact PI

Clinical Sciences Core (Core C)$344,320

P30 · FY2024 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit (CTU)$2,106,727

UM1 · FY2023 · AI · contact PI

Pharmacogenomics of HIV Therapy$816,720

R01 · FY2023 · AI · contact PI

Clinical Sciences Core (Core C)$261,146

P30 · FY2023 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit (CTU)$2,679,601

UM1 · FY2022 · AI · contact PI

Pharmacogenomics of HIV Therapy$814,283

R01 · FY2022 · AI · contact PI

Clinical Sciences Core (Core C)$254,028

P30 · FY2022 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit (CTU)$2,577,612

UM1 · FY2021 · AI · contact PI

Pharmacogenomics of HIV Therapy$838,752

R01 · FY2021 · AI · contact PI

Clinical Sciences Core (Core C)$663,722

P30 · FY2021 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$2,487,433

UM1 · FY2020 · AI · contact PI

Vanderbilt CTU SARS-CoV-2 Supplement$558,406

UM1 · FY2020 · AI · contact PI

Training and Mentoring Core$370,326

U54 · FY2020 · MD · contact PI

Clinical Sciences Core (Core C)$218,646

P30 · FY2020 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$2,941,559

UM1 · FY2019 · AI · contact PI

Pharmacogenomics of HIV Therapy$741,228

R01 · FY2019 · AI · contact PI

Clinical Science Core$328,563

P30 · FY2019 · AI · contact PI

Training and Mentoring Core$270,205

U54 · FY2019 · MD · contact PI

Vanderbilt HIV Clinical Trials Unit$1,615,311

UM1 · FY2018 · AI · contact PI

Pharmacogenomics of HIV Therapy$741,228

R01 · FY2018 · AI · contact PI

Clinical Science Core$342,170

P30 · FY2018 · AI · contact PI

Training and Mentoring Core$298,557

U54 · FY2018 · MD · contact PI

Vanderbilt HIV Clinical Trials Unit$1,003,759

UM1 · FY2017 · AI · contact PI

Pharmacogenomics of HIV Therapy$741,228

R01 · FY2017 · AI · contact PI

Clinical Science Core$379,679

P30 · FY2017 · AI · contact PI

Training and Mentoring Core$288,347

U54 · FY2017 · MD · contact PI

Pharmacogenomics of HIV Therapy$1,504,226

R01 · FY2016 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$1,224,853

UM1 · FY2016 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$395,433

UM1 · FY2016 · AI · contact PI

Training and Mentoring Core$312,210

U54 · FY2016 · MD · contact PI

Clinical Science Core$261,601

P30 · FY2016 · AI · contact PI

Pharmacogenomics of HIV Therapy$82,981

R01 · FY2016 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$1,603,813

UM1 · FY2015 · AI · contact PI

Pharmacogenomics of HIV Therapy$429,660

R01 · FY2015 · AI · contact PI

Clinical Science Core$234,648

P30 · FY2015 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$2,716,438

UM1 · FY2014 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$1,209,774

UM1 · FY2013 · AI · contact PI

Vanderbilt HIV Clinical Trials Unit$1,917,163

UM1 · FY2012 · AI · contact PI

Pharmacogenomics of HIV Therapy$768,079

R01 · FY2012 · AI · contact PI

Pharmacogenomics of HIV Therapy$774,768

R01 · FY2011 · AI · contact PI

CLINICAL DISCOVERY CORE$264,791

P30 · FY2011 · AI · contact PI

Pharmacogenomics of HIV Therapy$791,158

R01 · FY2010 · AI · contact PI

CLINICAL DISCOVERY CORE$461,895

P30 · FY2010 · AI · contact PI

Pharmacogenomics of HIV Therapy$802,962

R01 · FY2009 · AI · contact PI

CLINICAL DISCOVERY CORE$611,398

P30 · FY2009 · AI · contact PI

CNS Viral Dynamics and Cellular Immunity During AIDS$334,298

R01 · FY2009 · MH · contact PI

Pharmacogenomics of HIV Therapy$836,107

R01 · FY2008 · AI · contact PI

CLINICAL DISCOVERY CORE$531,699

P30 · FY2008 · AI · contact PI

CNS Viral Dynamics and Cellular Immunity During AIDS$330,117

R01 · FY2008 · MH · contact PI

CYP2B6 POLYMORPHISMS: NEVIRAPINE/EFAVIRENZ METABOLISM$11,145

M01 · FY2008 · RR · contact PI

CNS VIRAL DYNAMICS AND CELLULAR IMMUNITY DURING AIDS$1,433

M01 · FY2008 · RR · contact PI

BONE MINERAL DENSITY AND HIV INFECTION$81

M01 · FY2008 · RR · contact PI

CLINICAL DISCOVERY CORE$393,840

P30 · FY2007 · AI · contact PI

CNS Viral Dynamics and Cellular Immunity During AIDS$330,229

R01 · FY2007 · MH · contact PI

CYP2B6 POLYMORPHISMS: NEVIRAPINE/EFAVIRENZ METABOLISM$137,876

M01 · FY2007 · RR · contact PI

CNS VIRAL DYNAMICS AND CELLULAR IMMUNITY DURING AIDS$17,728

M01 · FY2007 · RR · contact PI

BONE MINERAL DENSITY AND HIV INFECTION$984

M01 · FY2007 · RR · contact PI

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,006,278

U01 · FY2006 · AI · contact PI

CNS Viral Dynamics and Cellular Immunity During AIDS$342,649

R01 · FY2006 · MH · contact PI

CLINICAL DISCOVERY CORE$306,343

P30 · FY2006 · AI · contact PI

PK INTERACTIONS BETWEEN ATAZANAVIR AND RIFAMPIN$14,452

M01 · FY2006 · RR · contact PI

BONE MINERAL DENSITY AND HIV INFECTION$7,781

M01 · FY2006 · RR · contact PI

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,466,770

U01 · FY2005 · AI

CNS Viral Dynamics and Cellular Immunity During AIDS$353,778

R01 · FY2005 · MH

BONE MINERAL DENSITY AND HIV INFECTION$8,904

M01 · FY2005 · RR

A5126-A PHASE II STUDY OF THE PREDICTIVE VALUE OF PHARMACOKINETIC-ADJUSTED PHEN$3,563

M01 · FY2005 · RR

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,556,340

U01 · FY2004 · AI

Pharmacokinetic Interaction Studies of Amprenavir (APV), Efavirenz (EFV), a S...$25,469

M01 · FY2004 · RR

RANDOMIZED, COMPARATIVE STUDY OF LOPINAVIR/RITONAVIR$5,092

M01 · FY2004 · RR

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,355,530

U01 · FY2003 · AI

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,207,252

U01 · FY2002 · AI

QUANTITATE CNS POTENCY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0

M01 · FY2002 · RR

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VS PROTEASE INHIBITOR$0

M01 · FY2002 · RR

EVALUATE INDINAVIR IN CSF IN HIV INFECTED PATIENTS RECEIVING MULTIPLE DOSES$0

M01 · FY2002 · RR

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$932,733

U01 · FY2001 · AI

QUANTITATE CNS POTENCY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0

M01 · FY2001 · RR

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VS PROTEASE INHIBITOR$0

M01 · FY2001 · RR

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VS PROTEASE INHIBITOR$0

M01 · FY2001 · RR

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VS PROTEASE INHIBITOR$0

M01 · FY2001 · RR

EVALUATE INDINAVIR IN CSF IN HIV INFECTED PATIENTS RECEIVING MULTIPLE DOSES$0

M01 · FY2001 · RR

EVALUATE INDINAVIR IN CSF IN HIV INFECTED PATIENTS RECEIVING MULTIPLE DOSES$0

M01 · FY2001 · RR

EVALUATE INDINAVIR IN CSF IN HIV INFECTED PATIENTS RECEIVING MULTIPLE DOSES$0

M01 · FY2001 · RR

QUANTITATE CNS POTENCY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0

M01 · FY2001 · RR

QUANTITATE CNS POTENCY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0

M01 · FY2001 · RR

VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT$1,018,550

U01 · FY2000 · AI

EVALUATE INDINAVIR IN CSF IN HIV INFECTED PATIENTS RECEIVING MULTIPLE DOSES$592

M01 · FY2000 · RR

QUANTITATE CNS POTENCY OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$592

M01 · FY2000 · RR

NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR VS PROTEASE INHIBITOR$0

M01 · FY2000 · RR